Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (DE:6LP)
FRANKFURT:6LP
RESEARCH TOOLSreports
Total Valuation
Bolt Biotherapeutics has a market cap or net worth of $10.84M. The enterprise value is €28.66M.
Market Cap$10.84M
Enterprise Value€28.66M
Share Statistics
Bolt Biotherapeutics has 38,339,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,339,700
Owned by Insiders11.12%
Owned by Institutions41.22%
Financial Efficiency
Bolt Biotherapeutics’s return on equity (ROE) is -1.10 and return on invested capital (ROIC) is -84.91%.
Return on Equity (ROE)-1.10
Return on Assets (ROA)-0.63
Return on Invested Capital (ROIC)-84.91%
Return on Capital Employed (ROCE)-0.87
Revenue Per Employee147.88K
Profits Per Employee-1.21M
Employee Count52
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bolt Biotherapeutics is -0.32. Bolt Biotherapeutics’s PEG ratio is 0.32.
PE Ratio-0.32
PS Ratio0.00
PB Ratio0.26
Price to Fair Value0.36
Price to FCF-0.21
Price to Operating Cash Flow-0.21
PEG Ratio0.32
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of 7.69M and earned -63.12M in profits. Earnings per share was -1.65.
Revenue7.69M
Gross Profit5.51M
Operating Income-73.05M
Pretax Income-63.12M
Net Income-63.12M
EBITDA-66.45M
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was -57.90M and capital expenditures -41.00K, giving a free cash flow of -57.94M billion.
Operating Cash Flow-57.90M
Free Cash Flow-57.94M
Free Cash Flow per Share-1.51
Dividends & Yields
Bolt Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change-62.41%
50-Day Moving Average0.32
200-Day Moving Average0.48
Relative Strength Index (RSI)40.02
Average Volume (3m)0.00
Important Dates
Bolt Biotherapeutics upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Bolt Biotherapeutics as a current ratio of 3.20, with Debt / Equity ratio of 52.79%
Current Ratio3.20
Quick Ratio3.20
Debt to Market Cap1.23
Net Debt to EBITDA-0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bolt Biotherapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bolt Biotherapeutics EV to EBITDA ratio is -0.58, with an EV/FCF ratio of -0.63.
EV to Sales5.00
EV to EBITDA-0.58
EV to Free Cash Flow-0.63
EV to Operating Cash Flow-0.63
Balance Sheet
Bolt Biotherapeutics has $38.84M in cash and marketable securities with $24.71M in debt, giving a net cash position of -$14.13M billion.
Cash & Marketable Securities$38.84M
Total Debt$24.71M
Net Cash-$14.13M
Net Cash Per Share-$0.37
Tangible Book Value Per Share$1.50
Margins
Gross margin is -324.22%, with operating margin of -949.91%, and net profit margin of -820.78%.
Gross Margin-324.22%
Operating Margin-949.91%
Pretax Margin-820.78%
Net Profit Margin-820.78%
EBITDA Margin-864.17%
EBIT Margin-887.33%
Analyst Forecast
The average price target for Bolt Biotherapeutics is $1.77, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.77
Price Target Upside579.68% Upside
Analyst ConsensusHold
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―